Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $0.94.

  • Seres Therapeutics' EPS (Basic) fell 9191.75% to $0.94 in Q3 2025 from the same period last year, while for Sep 2025 it was $16.3, marking a year-over-year increase of 96535.95%. This contributed to the annual value of $0.81 for FY2024, which is 15437.64% up from last year.
  • As of Q3 2025, Seres Therapeutics' EPS (Basic) stood at $0.94, which was down 9191.75% from -$2.27 recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' EPS (Basic) ranged from a high of $13.87 in Q4 2024 and a low of -$5.49 during Q1 2024
  • Moreover, its 5-year median value for EPS (Basic) was -$0.49 (2022), whereas its average is $0.75.
  • Over the last 5 years, Seres Therapeutics' EPS (Basic) had its largest YoY gain of 523703.7% in 2024, and its largest YoY loss of 130555.56% in 2024.
  • Over the past 5 years, Seres Therapeutics' EPS (Basic) (Quarter) stood at -$0.55 in 2021, then grew by 1.82% to -$0.54 in 2022, then skyrocketed by 50.0% to -$0.27 in 2023, then soared by 5237.04% to $13.87 in 2024, then tumbled by 93.22% to $0.94 in 2025.
  • Its EPS (Basic) stands at $0.94 for Q3 2025, versus -$2.27 for Q2 2025 and $3.76 for Q1 2025.